Table 2 Treatment overview of patients included within the study.
Characteristic | Value (%) |
|---|---|
n = 18 | |
Treatment Lines prior to Transplant | |
1 | 12 (67%) |
2 | 4 (22%) |
3 | 2 (11%) |
First line treatment | |
Lenalidomide, Bortezomib, and Dexamethasone | 15 (83%) |
Daratumumab, bortezomib, cyclophosphamide, and dexamethasone | 3 (17%) |
Second line treatment | |
None | 12 (67%) |
Lenalidomide, Dexamethasone | 3 (11%) |
Carfilzomib, Lenalidomide and Dexamethasone | 2 (11%) |
Daratumumab, bortezomib, cyclophosphamide, and dexamethasone | 1 (6%) |
Third line Treatment | |
None | 16 (89%) |
Pomalidomide, dexamethasone | 2 (11%) |
Stem Cell Mobilization | |
Cytoxan | 18 (100%) |
Conditioning | |
Melphalan | 18 (100%) |
GVHD | |
No | 17 (94%) |
Yes | 1 (6%) |
Maintenance | |
Lenalidomide | 12 (67%) |
Bortezomib | 6 (33%) |
Number of Treatments for Acute Leukemia | |
1 | 9 (50%) |
2 | 7 (39%) |
3 | 2 (11%) |
Acute Leukemia Remission | |
No | 8 (44%) |
Yes | 10 (56%) |
Myeloma Remission | |
No | 3 (17%) |
Yes | 15 (83%) |
